Publications about WM from IWMF Patient Advocacy Partners

Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 1.2025, NCCN Clinical Practice Guidelines in Oncology. Kumar, S. K., Callander, N. S., Adekola, K., Anderson, L. D., Jr, Baljevic, M., Baz, R., Campagnaro, E., Costello, C., D’Angelo, C., Derman, B., Devarakonda, S., Elsedawy, N., Godara, A., Godby, K., Hillengass, J., Holmberg, L., Htut, M., Huff, C. A., Hultcrantz, M., Kang, Y., Larson, S., Lee, H., Liedtke, M., Martin, T., Omel, J., Robinson, T., Rosenberg, A., Schroeder, M. A., Sherbenou, D., Suvannasankha, A., Valent, J., Varshavsky-Yanovsky, A. N., Vogl D., Kovach E. & Kumar, R. (2025). Journal of the National Comprehensive Cancer Network. The data from key PubMed articles as well as articles from additional sources deemed as relevant to these guidelines as discussed by the panel during the NCCN Guidelines update have been included in this 2025 version of the discussion section. Recommendations for which high-level evidence is lacking are based on the panel’s review of lower-level evidence and expert opinion. The complete details of the development and updates of the NCCN Guidelines are available at NCCN.org.

Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. Kumar, S. K., Callander, N. S., Adekola, K., Anderson, L. D., Jr, Baljevic, M., Baz, R., Campagnaro, E., Castillo, J. J., Costello, C., D’Angelo, C., Derman, B., Devarakonda, S., Elsedawy, N., Garfall, A., Godby, K., Hillengass, J., Holmberg, L., Htut, M., Huff, C. A., Hultcrantz, M., Kang, Y., Larson, S., Lee, H., Liedtke, M., Martin, T., Omel, J., Robinson, T., Rosenberg, A., Sborov, D., Schroeder, M. A., Sherbenou, D., Suvannasankha, A., Valent, J., Varshavsky-Yanovsky, A. N., Snedeker, J., & Kumar, R. (2024). Journal of the National Comprehensive Cancer Network, 22(1D), 1-19. Retrieved Feb 4, 2024, from https://doi.org/10.6004/jnccn.2024.0001 The data from key PubMed articles as well as articles from additional sources deemed as relevant to these guidelines as discussed by the panel during the NCCN Guidelines update have been included in this 2024 version of the discussion section. Recommendations for which high-level evidence is lacking are based on the panel’s review of lower-level evidence and expert opinion. The complete details of the development and updates of the NCCN Guidelines are available at NCCN.org.

NCCN Guidelines for Patients with WM, 2022 (link is external). An excellent addition to the NCCN’s extensive series of patients’ guides for a variety of cancers, has been endorsed by the IWMF, and has been adopted as a supplement to the IWMF’s library of booklets, Treatment Guides, and Fact Sheets. WM patients and caregivers are certain to find this new 2022 booklet to be a relevant and informative resource that will help people living with WM talk to their physicians about the best treatment options for their disease. The NCCN Guidelines for Patients with WM (link is external) currently is available only in English.

Chimeric Antigen Receptor (CAR) T-Cell Therapy Facts. This fact sheet from The Leukemia & Lymphoma Society (LLS) provides provides information on how CAR T-cell therapy may work, the possible side effects of this treatment approach and its potential role in the treatment of blood cancer. A brief overview of the immune system and immunotherapy is included to help patients understand the information provided in this publication.

Waldenstrom Macroglobulinemia(link is external). One of many fact sheets from the The Leukemia & Lymphoma Society (LLS), this overview of WM includes current treatment options, treatments under investigation, and information about the LLS Support Network, and their varied educational resources.

Cancer and Your Finances(link is external). This free workbook from Leukemia and Lymphoma Society covers the following topics and includes worksheets to help you get and stay organized.